Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
ECOG performance status 0-2
Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)
Expected survival of greater than 3 months
Age: 18-75 years
The patients with key organs maintenance of basic function: Hemoglobin ≥ 9g/dL, White Blood Cell ≥ 3×109/L, Neutrophil count ≥ 1.5×109/L, platelets ≥ 80×109/L, total bilirubin \< 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2.5 of the upper normal values, the serum creatinine \< 1.5 times of the upper normal values
Signed informed consent document on file.
You may not be if
Brain metastasis without local treatment before
Patients without the treatment of Icotinib before or the therapeutic time less than 3 months
More than 3 extracranial organs have metastatic lesions
The patient with other type malignant tumors before
The patient with fertility capacity, but without contraceptive application
Clareo Health | Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
